1270P Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes

摘要: BackgroundBone metastases (BMs) occur in 20-40% of metastatic NSCLC. BMs adversely affect patient (pt) quality of life and are associated with increased mortality, but have not been typically used as stratification factor for clinical trials. Our aim was to evaluate genomic alterations associated with BMs at diagnosis in NSCLC and their impact on survival outcomes.MethodsThe AACR GENIE Biopharma Collaborative (BPC) is a registry of clinical and genomic data from patients with NSCLC who had tumor sequencing (55-500 genes) from 2015-2017 at four academic centers. Imaging reports and medical oncologists’ clinical notes were retrospectively curated using the PRISSMM framework. Kaplan–Meier (KM) method was used to estimate the median overall survival (OS). Hazard ratio (HR) and 95% confidence intervals (95% CI) were calculated using the Cox Proportional-Hazards Model with survival endpoints …